Use Of An Anti-Pd-1 Antibody In Combination With An Anti-Cd30 Antibody In Lymphoma Treatment

Patent No. EP3464368 (titled "Use Of An Anti-Pd-1 Antibody In Combination With An Anti-Cd30 Antibody In Lymphoma Treatment") was filed by Bristol Myers Squibb on Jun 1, 2017. The application was issued on Jun 28, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STRAWMANMar 25, 2024HOFFMANN EITLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3464368

BRISTOL MYERS SQUIBB
Application Number
EP17730629A
Filing Date
Jun 1, 2017
Status
Granted And Under Opposition
May 26, 2023
Publication Date
Jun 28, 2023